Please assess the completion status of the following clinical trial:

Trial Title: Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must sign an approved informed consent form (ICF)~* Histologically or cytologically confirmed epithelial ovarian/fallopian tube/primary peritoneal carcinoma~* Patients had to have received a front-line, platinum/taxane based chemotherapy regimen~* Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer or progressed within six months of completing the most recent platinum-based chemotherapy~* Participants must have received prior platinum-based chemotherapy for management of primary disease but must not have received more than 3 prior systemic cytotoxic regimens.~* Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area and increased Ca 125~* A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment~* Age 20-75 years old~* Performance status (WHO) 0-2~* Life expectancy of at least three months~* Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3)~* Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl)~Exclusion Criteria:~* prior therapy with vinorelbine or gemcitabine~* treatment with \> 2 cytotoxic regimens (including primary platinum and taxane chemotherapy)~* Serious comorbidities (as determined by the investigator) such as, but not limited to, active congestive heart failure, recent myocardial infarction or active infection.~* Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).~* Symptomatic central nervous system (CNS) metastasis.~* Uncontrolled intestinal obstruction~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational~* Pregnant or nursing.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vinorelbine and Gemcitabine (Type: EXPERIMENTAL): Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).